Close



Nov 13, 2023 07:05AM
Aug 22, 2023 04:01PM
Mar 23, 2023 04:00PM
Dec 7, 2022 04:00PM
Nov 10, 2022 04:00PM
Aug 11, 2022 04:00PM
Jul 18, 2022 05:12PM Celcuity (CELC) Granted FDA Breakthrough Therapy Designation for Gedatolisib
Jul 18, 2022 05:10PM
May 16, 2022 04:00PM
Mar 23, 2022 04:00PM
Jan 18, 2022 07:31AM
Jan 18, 2022 07:30AM
Dec 10, 2021 09:31AM
Dec 10, 2021 09:30AM Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symp
Nov 15, 2021 08:00AM
Nov 8, 2021 04:00PM
Oct 18, 2021 04:11PM
Oct 18, 2021 04:09PM
Aug 9, 2021 04:00PM
Jun 29, 2021 09:27AM
Jun 9, 2021 09:10AM Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
May 10, 2021 04:00PM
Apr 12, 2021 04:00PM
Apr 9, 2021 09:31AM
Apr 8, 2021 05:45PM
Apr 8, 2021 04:07PM
Apr 8, 2021 04:05PM
Apr 8, 2021 04:03PM Celcuity (CELC) Announces Worldwide Licensing Agreement with Pfizer (PFE) to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
Apr 8, 2021 04:02PM
Mar 16, 2021 04:00PM
Mar 16, 2021 04:00PM
Jan 27, 2021 05:31PM
Dec 23, 2020 07:06AM
Dec 23, 2020 07:00AM
May 7, 2020 04:00PM Celcuity Reports First Quarter 2020 Financial Results and Recent Business Highlights
Dec 5, 2019 10:24AM
Oct 16, 2018 05:51PM
May 14, 2018 04:00PM

251,368 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All